



2021 Fall

gcccw

Global Commercialization
Conference and Workshop

Hosted by



Ministry of Science and ICT



Ministry of Trade,
Industry and Energy



DAEJEON METROPOLITAN CITY



KAIST

JSTD Jiangsu, China
Science and Technology Department

Organized by



Korea Technology and Information
Promotion Agency for SMEs

ITIRI

Sponsored by



Creating Value in the Global Commercialization Ecosystem through Technology Innovation

KAIST GCC (Global Commercialization Center) heartily invites you to partake in the 13th Global Commercialization Conference and Workshop (GCCW) being held on November 22-24, 2021. The GCCW, under the theme of 'Value Creation of Global Commercialization Ecosystem through Technology Innovation', aims to respond to the rapidly changing global industrial environment by discovering global cooperative networks to create business opportunities.

The GCCW Program include: First, discussion on strategies for entering the U.S. market for promising Bio companies in ChungCheongBuk-Do. Second, trend of ICT convergence technology development and application along with discussion on cooperation for global technology commercialization. Third, Korea-China global commercialization strategy and business consultation in Bio-health sector. Fourth, share strategies and achievements of global up program for promising SMEs, and finally discussion on building a global network for collaboration in the mobility sector.

The GCCW will bring together cooperative partners from all sectors-government, research institute, and industry-to an innovative platform to create collaboration opportunities through global technology commercialization. We look forward to your active participation in the GCCW for a mutually beneficial relationship. We are grateful to all the presenters and participants at home and abroad, and express our sincere gratitude for dedicating their valuable time and efforts to support the 2021 Fall GCCW.

2021.

11.22 Mon ~ **24** Wed

SUPEX Hall, KAIST Munji Campus

Online broadcast



zoom | Main, HALL A

zoom | Session 3, Hall B



SESSION 3

11/23

10:00 ~ 18:00

Korea-China Bio Technology Commercialization

(Korean/Chinese live interpretation)

Korea-China Global
Commercialization Strategy and
Business Consultation in Bio-Health
Sector

Hall A

10:00~10:06 *Opening Address*
Mun-Kee Choi, Director, KAIST GCC

10:06~10:10 **JSTD, China**

10:10~10:17 **Hyun Song, Jang**, Director of Collaborative Business Division

10:17~10:20 *Congratulatory Address*
Suzhou Industrial Park (SIP)

10:20~10:40 *Special Talk*
Byung-Hwan Hyeon, Professor, Graduate School at Daejeon University
KOREA Bio Policy & Industry

10:40~11:00 *Special Talk*
JSTD, China
Jiangsu Bio-Health Industry Policy and Ecosystem

Panel Discussion
Moderator | **Byung-Hwan Hyeon**, Professor, Graduate School at Daejeon University

Youngjuoo Koh, R&D Project Manager, TIPA

Heung-Yeol Kim, President, National Biotech Policy Research Center

11:00~12:20 **Yang Han**, Director of Biomedical Division, National Innovation Center
- Yangtze Delta

Li Yi, Vice President, PharmaBlock

Li Baijun, General Manager, Jiangsu Taicang Biomedical Industrial Park

12:20 - 13:30 **Lunch**

SESSION 3

11/23

10:00 ~ 18:00

Korea-China Bio Technology Commercialization

(Korean/Chinese live interpretation)

Korea-China Global
Commercialization Strategy and
Business Consultation in Bio-Health
Sector

Hall A

Company Presentations

Moderator | Suk Kyoon Yoon, CEO, IMPART

13:30~13:55	Hye Seong Lim , CEO, PANOLOS BIOSCIENCE <i>Preclinical Development of Next Generation Anti-Angiogenesis Therapy for Solid Cancer</i>
13:55~14:20	Luye Pharma Group
14:20~14:45	Doo Young Jung , CEO, PINOTBIO <i>Pinot-ADC, a novel antibody-drug conjugate (ADC) platform for 3rd generation ADC development</i>
14:45~15:10	Lu Yifeng , CEO, Hainai Hailing Chemipharm Corporation Ltd (Suzhou) <i>International Cooperation - Latamoxef Sodium for Injection in Greater China Market</i>
15:10~15:30	Break
15:30~15:55	Li Yi , Vice President, PharmaBlock
15:55~16:20	Changgun Kim , R&D Business Manager, GNT Pharma Co., Ltd <i>Multi-target neuroprotection drugs. (Innovative therapy for neurological diseases)</i>
16:20~16:45	Kachin Wong , CEO, SPES Tech <i>Smart Protein Engineering Solution</i>
16:45~17:10	Andrew Han , Senior Vice President, GBIOLOGICS Inc. <i>Development of Rheumatoid Arthritis drug and KRAS mutant cancer drug using a new recombinant protein 'sGal-9'</i>
17:10~17:35	Li Xinfang , CEO, MabPlex International Ltd. <i>R&D and innovation of ADC drugs</i>
17:35~18:00	Dong-Ha Shin , General Manager, InsectBiotech <i>Arazyme and Enzyme products</i>

SESSION 3

11/23

10:00 ~ 18:00

Korea-China Bio Technology Commercialization

(Korean/Chinese live interpretation)

Korea-China Global
Commercialization Strategy and
Business Consultation in Bio-Health
Sector

Hall B


Company Presentations

Moderator | **Sun-Il Kim**, Professor, Hanyang University

- | | |
|-------------|--|
| 13:30~13:55 | Julie Yi , Managing Director, Shanghai OPM Biosciences Co., Ltd.
<i>Cell Culture Solutions - Optimization makes differences</i> |
| 13:55~14:20 | Sangjoon Park , CEO, Medical IP
<i>AI-powered Medical Imaging Segmentation Software and CAD/CAM</i> |
| 14:20~14:45 | Shen Guofeng , Co-Founder and CEO, SHENDE
<i>SHENDE MR-PHIFU Non-invasive Treatment System</i> |
| 14:45~15:10 | Garnet Kim , Lead of Open Innovation, PharmaResearch
<i>Introduction for PharmaResearch Co. & Conjuran for Exclusive license partnering in China</i> |
| 15:10~15:35 | Li Jing , CEO, Nanjing Anxingyue Medical Technology Co., Ltd
<i>Vital Signs based on Optical Fiber Sensor</i> |
| 15:35~16:00 | Pilhan Kim , CEO&CTO, IVIM Technology
<i>Intravital Microscopy (IVM) for In Vivo Live Cell Imaging and Analysis</i> |
| 16:00~16:20 | Break |
| 16:20~16:45 | Peter Moon , CEO, IMBDX
<i>Analysis of circulating tumor DNA for Cancer Patients and for the success of Clinical trials</i> |
| 16:45~17:10 | Yang Shanshan , Early Screening Project Leader, Geneseeq |
| 17:10~17:35 | YoungHyeon Nam , CEO, NuriBio
<i>Early diagnosis kit of pancreas, colon & lung cancers based on miRNA expression pattern analysis using a super-sensitive gene detection method (PROMERTM)</i> |
| 17:35~18:00 | Liu Chunxia , Technical Director, Standard Testing Group Co.,Ltd.
<i>Drug quality research ideas and experience sharing</i> |

directions

SUPEX Hall,
KAIST Munji Campus



KAIST
kaist.ac.kr

KAIST CC
gcc.kaist.ac.kr

iTTP @ KAIST
GLOBAL IT LEADERS
ittp.kaist.ac.kr

zoom Online broadcast 

https://www.gccw.co.kr/pre/pre_form.asp